<?xml version='1.0' encoding='utf-8'?>
<document id="25162212"><sentence text="Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantation." /><sentence text="Tacrolimus (TAC) is a known substrate for cytochrome P450 (CYP) enzyme" /><sentence text=" CYP enzyme activity can be modulated by activation of IL-2 receptors (IL-2R) expressed on hepatocytes and intestinal cells" /><sentence text=" IL-2R antagonists (IL-2RA) may promote preferential binding of circulating IL-2 to IL-2Rs on these cells by blocking IL-2Rs on activated T cells" /><sentence text=" This downregulates CYP enzymes, leading to increased calcineurin inhibitor levels" /><sentence text=" This analysis evaluates the significance of this drug-drug interaction in kidney transplant recipients" /><sentence text="" /><sentence text="Data were used from a previous 5-year randomized, controlled study comparing outcomes associated with maintenance immunosuppression using 2 corticosteroid regimens: long-term therapy versus early withdrawal"><entity charOffset="140-154" id="DDI-PubMed.25162212.s8.e0" text="corticosteroid" /></sentence><sentence text=" Patients received either IL-2RAs or rabbit anti-thymocyte globulin (rATG) for induction" /><sentence text=" Serial TAC trough levels and doses were compared between induction agents within each corticosteroid arm"><entity charOffset="87-101" id="DDI-PubMed.25162212.s10.e0" text="corticosteroid" /></sentence><sentence text=" Rejection rates, patient/graft survival, and TAC adverse effects were also evaluated" /><sentence text="" /><sentence text="In the first week, IL-2RA-treated patients achieved significantly higher trough levels and required lower doses (in milligram per kilogram) to achieve target levels than rATG-treated patients" /><sentence text=" No significant differences in rejection rates, patient/graft survival, or rate of adverse effects were observed through 1 year" /><sentence text="" /></document>